NCT07090538View on ClinicalTrials.gov

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Neuroblastoma
Interventions
DRUG

Eliglustat

Drug: GM-CSF + Eliglustat Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and GSL Synthetase Inhibitor

Trial Locations (2)

100853

Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing

Unknown

Department of Pediatrics, The First Medical Center, Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER